Alexandra C. Thiry

Weitere Beteiligungen

• 09.12.2022

  15:30 – 15:35 3 Min. 2 Min.

  • ePoster
  • P115

  Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience

   CGRP inhibitors in the clinic, Migraine
• 09.12.2022

  15:40 – 15:45 3 Min. 2 Min.

  • ePoster
  • P122

  Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study

   CGRP inhibitors in the clinic, Migraine
• 09.12.2022

  15:45 – 15:50 3 Min. 2 Min.

  • ePoster
  • P123

  Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine

   CGRP inhibitors in the clinic, Migraine
• 09.12.2022

  16:40 – 16:45 3 Min. 2 Min.

  • ePoster
  • P149

  Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study

   CGRP inhibitors in the clinic, Migraine
• 09.12.2022

  16:45 – 16:50 3 Min. 2 Min.

  • ePoster
  • P148

  Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

   CGRP inhibitors in the clinic, Migraine